Pancreas Cancer Specialized Program of Research Excelle*

这个专门的胰腺癌卓越研究项目(孢子)的目标是将 杰出的假说驱动的基础研究，用于拯救生命的临床治疗。胰腺癌是一种 致死患者的毁灭性癌症，不仅因为它可能极具侵袭性，还因为它 诊断晚了。这个孢子是乔治敦大学、盖辛格健康中心 系统和INDIVUMED德国研究所与德国医院财团合作，带来了 一所优秀的学术机构，一个庞大的地区医疗体系，以及一个德国基础和 临床研究系统，以解决胰腺癌的生物学和临床护理。项目1的重点是 抑制一种新的肝素结合生长因子促进肿瘤侵袭转移的作用 胰腺癌。项目2的重点是中性调节蛋白和多营养因子在已建立的模型中的作用。 神经元：肿瘤细胞相互作用的目标是开发阻止恶性神经侵袭的方法 最终可能有助于缓解疾病的胰腺细胞。项目3的重点是最近的发现， 核受体辅活化子AIB1在胰腺癌细胞及邻近内皮细胞中的抑制作用 可能通过阻断多种生长因子的信号来促进细胞凋亡。Ras/MAP激酶的激活 发生在高达90%的胰腺癌中的途径是放射治疗新方法的焦点 项目4中的致敏作用。乔治敦大学的研究人员已经开发出一种RAFL反义抑制剂，它是 已经处于第一阶段试验，并在该途径中开发了其他互补的分子靶点。 此外，这个孢子正在发展基础设施和资源，以获取组织和体液 来自胰腺肿瘤库和血清检测和分子鉴定核心的患者 预计每年会有120例根治性切除手术。孢子将利用生物统计核心来确保所有 项目具有适当的设计、分析方法和用于报告患者的集成数据库 结果。此外，孢子将支持旨在产生新知识的开发项目。 以及及早发现和促进专门从事翻译工作的职业发展道路的方法 胰腺癌的研究。这种孢子也与其他植物的孢子建立了相互作用。 机构以及其他由NCI和NIH资助的项目，以促进积极发展 控制胰腺癌的新疗法

The goal of this Specialized Program of Research Excellence (SPORE) in pancreas cancer is to translate outstanding hypothesis-driven basic research into clinical treatment that saves lives. Pancreatic cancer is a devastating cancer that kills patients not just because it may be extremely aggressive but also because it is diagnosed late. This SPORE is a unique collaboration between Georgetown University, Geisinger Health System and INDIVUMED a German Research Institute with a German hospital consortium that brings together an outstanding academic institution, a large regional healthcare system and a German basic and clinical research system to address the biology of pancreatic cancer and clinical care. Project 1 focuses on inhibition of pleiotrophin, a novel heparin-binding growth factor that promotes invasion and metastasis in pancreatic cancer. Project 2 focuses on the role of neuregulins and pleiotrophin in an established model of neuron:tumor cell interaction with the goal of developing methods to block neural invasion by malignant pancreas cells that may ultimately aid in disease palliation. Project 3 focuses on recent findings that inhibition of the nuclear receptor coactivator AIB1 within pancreas cancer cells and adjacent endothelium may block signaling from multiple growth factors to enhance apoptosis. The activation of the ras/MAP kinase pathway that occurs in up to 90% of pancreas cancer is the focus for novel approaches to radiation sensitization in Proiect 4. Investigators at Georgetown have developed a rafl antisense inhibitor that is already in Phase I trial and have developed other molecular targets in the pathway that are complementary. In addition, this SPORE is developing the infrastructure and resources to acquire tissues and bodily fluids from patients (Pancreatic Tumor Bank and Serum Detection & Molecular Identification Cores) with an expected 120 curative resections a year. The SPORE will utilize a biostatistical core to insure that all projects have appropriate designs, methods of analysis, and an integrated database for reporting patient outcomes. Further, the SPORE will support developmental projects designed to generate new knowledge and approaches to early detection and promote the development of career tracks dedicated to translational research in pancreatic cancer. This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer